Simple blood test could spot Crohn's and colitis earlier
NCT ID NCT03833310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at four substances in the blood (Osteoprotegerin, sRANKL, NFkB, and TFF3) to see if they could help diagnose inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. Researchers measured these markers in 70 newly diagnosed patients before and after treatment. The goal is to find a noninvasive, accurate way to diagnose IBD without relying solely on endoscopy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood test measuring Osteoprotegerin, sRANKL, NFkB, and TFF3
- What this could lead to
- If successful, these blood markers could help doctors diagnose Crohn's disease and ulcerative colitis more accurately and less invasively.
- What could go wrong
- This is a small, completed study with only 70 participants. The markers may not prove accurate enough for routine use, and results need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assuit Medical University
Asyut, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?